NKTR
Nektar Therapeutics
NASDAQ: NKTR · HEALTHCARE · BIOTECHNOLOGY
$83.20
-0.73% today
Updated 2026-04-29
Market cap
$2.76B
P/E ratio
—
P/S ratio
50.03x
EPS (TTM)
$-9.73
Dividend yield
—
52W range
$8 – $109
Volume
1.1M
Nektar Therapeutics (NKTR) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-90.9%
Last 4 quarters
Revenue YoY growth
-25.3%
Most recent quarter
EPS YoY growth
-759.9%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+3.0%
Last 3 reports
Positive reaction rate
100%
3 of 3 quarters
Largest single-day move
+3.3%
2025-08-08
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-13 | $-1.29 | +63.1% | $70.36 | $72.21 | +2.6% |
| 2025-11-06 | $-1.87 | -869.9% | $54.26 | $55.97 | +3.2% |
| 2025-08-08 | $-2.95 | -1375.0% | $21.75 | $22.47 | +3.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-3.50 | $-1.29 | +63.1% | $21.81M | -25.3% |
| 2025-09-30 | $-0.19 | $-1.87 | -869.9% | $11.79M | -51.1% |
| 2025-06-30 | $-0.20 | $-2.95 | -1375.0% | $11.18M | -52.4% |
| 2025-03-31 | $-0.19 | $-0.24 | -26.5% | $10.46M | -51.7% |
| 2024-12-31 | $-0.20 | $-0.15 | +23.1% | $29.18M | +22.1% |
| 2024-09-30 | $-0.21 | $-0.18 | +14.3% | $24.12M | -0.1% |
| 2024-06-30 | $-0.20 | $-0.25 | -25.0% | $23.49M | +14.6% |
| 2024-03-31 | $-0.19 | $-0.19 | +0.0% | $21.64M | +0.2% |
| 2023-12-31 | $-0.21 | $-0.22 | -4.8% | $23.89M | — |
| 2023-09-30 | $-0.20 | $-0.24 | -20.0% | $24.14M | — |
| 2023-06-30 | $-0.28 | $-0.27 | +3.6% | $20.50M | — |
| 2023-03-31 | $-0.25 | $-0.32 | -28.0% | $21.59M | — |
Frequently asked questions
Has Nektar Therapeutics beaten earnings estimates?
Nektar Therapeutics has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -90.9% over the last 4 quarters.
How does NKTR stock react to earnings?
NKTR stock has moved an average of +3.0% in the trading day following earnings over its last 3 reports, with positive reactions in 100% of those quarters.
What is Nektar Therapeutics's revenue growth rate?
Nektar Therapeutics reported year-over-year revenue growth of -25.3% in its most recent quarter, with EPS growing -759.9% year-over-year.